REMARKS

Currently claims 1-14, 16, and 18 are pending. Please cancel claims 15 and 17. Applicants amend the claims to remove unintentional duplication, place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. No new matter is added through this amendment.

Applicants amend the specification for purposes of adding the priority information.

The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

√John L. Lemanowicz Attorney for Applicant

Registration No. 37,380

6/6/05

Date: GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-8247 Facsimile: 919-483-7988